Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Conference Call March 6, 2023 8:30 AM ET

Company Participants

Stuart Henderson - Vice President, Corporate Development & Investor Relations

Will Chou - Chief Executive Officer

Mark Forman - Chief Medical Officer

Simona King - Chief Financial Officer

Conference Call Participants

Brendan Smith - Cowen

Omari Baruti - Goldman Sachs

Laura Chico - Wedbush

Yun Zhong - BTIG

Whitney Ijem - Canaccord

Operator

Good morning, and welcome to the Passage Bio Fourth Quarter and Full Year 2022 Financial Operating Results Conference Call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request.

Now, I'd like to turn it over to Stuart Henderson, Vice President, Corporate Development and Investor Relations. Stuart, please proceed.

Stuart Henderson

Thank you, operator. This morning we issued a press release that outlines the topics we plan to discuss today. This release is available on the Passage Bio website under the Press Releases and Statements section of Investors and News.

On today's call, Chief Executive Officer, Will Chou, will review our fourth quarter 2022 and recent business highlights; Mark Forman, our Chief Medical Officer, will review our clinical programs; and Simona King, our Chief Financial Officer, will review our fourth quarter and full year 2022 financial results.

Before we begin, please note that today's call may include a number of forward-looking statements. These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements.

Please refer to the company's filings with the SEC for information concerning risk factors that could cause its actual results to differ materially from expectations, including any forward-looking statements made on this call. Except as required by law, the company disclaims any obligation to publicly update or revise any forward-looking statements to account for or reflect events or circumstances that occur after this call.

It is now my pleasure to pass the call over to Will.

Will Chou

Thanks, Stuart, and thank you all for joining us this morning. I want to begin today's call by briefly reflecting on this past year. By honing our strategy and operational focus, we ended 2022 in a strong position and I'm proud of the work the team did to lay the groundwork and build the momentum needed to ensure we can deliver meaningful clinical data from our two lead programs in 2023.